Fredag 10 Januari | 03:33:45 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-28 N/A Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
2024-11-13 18:36:00 Gubra announces positive GUBamy Phase 1 SAD data (correction) pdf download
2024-11-13 17:41:00 Gubra announces positive GUBamy Phase 1 SAD data pdf download
2024-11-07 07:30:00 Trading statement Q3-2024: Another strong quarter pdf download
2024-09-06 21:42:00 Major shareholder announcement pdf download
2024-08-22 07:30:00 Interim report H1 2024: Strong performance across Gubra pdf download
2024-08-21 17:12:00 Gubra raises financial outlook for 2024 pdf download
2024-05-07 07:30:00 Trading statement Q1-2024: Strong start to the year pdf download
2024-05-06 17:15:00 Gubra raises financial outlook for 2024 pdf download
2024-04-17 07:30:00 Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss pdf download pdf download
2024-04-04 12:32:00 RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024 pdf download
2024-03-26 22:45:00 Major shareholder announcement: The Capital Group Companies Inc. pdf download pdf download pdf download
2024-03-25 09:56:00 Major shareholder announcement pdf download pdf download
2024-03-06 09:00:00 NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024 pdf download
2024-01-26 13:33:00 Gubra concludes the research agreement with UK Biotech pdf download
2023-11-08 07:30:00 Trading statement Q3-2023: Continued strong performance pdf download
2023-11-01 11:01:00 Gubra strengthens Board of Directors pdf download img download img download
2023-11-01 10:40:00 Gubra - Extraordinary general meeting pdf download
2023-10-26 12:35:00 Gubra enters into a Market Maker Agreement pdf download
2023-10-26 08:01:00 Gubra raises financial guidance for full-year 2023 pdf download
2023-10-24 07:30:00 Gubra opens its first US office in Boston pdf download
2023-10-09 14:00:00 NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING pdf download
2023-09-06 09:58:00 Gubra submits clinical trial application (CTA) for first-in-human amylin trial pdf download
2023-09-01 11:41:00 Completion of share buy-back programme pdf download Excel download
2023-08-28 08:15:00 Gubra resumes its share buy-back programme to hedge incentive scheme obligations pdf download
2023-08-25 07:30:00 Interim report H1-2023: Strong performance and ahead of expectations pdf download
2023-08-23 16:44:00 Gubra announces termination of collaboration with Bayer pdf download
2023-08-21 15:29:00 Gubra A/S announces signing of collaboration agreement with Hemab ApS pdf download
2023-08-15 13:19:00 Gubra raises financial guidance for full-year 2023 pdf download
2023-07-28 19:41:00 Information on share buy-back programme pdf download pdf download
2023-06-30 08:00:00 Gubra launches share buy-back programme to hedge incentive scheme obligations pdf download
2023-06-29 07:00:00 Gubra acquires research service provider MiniGut ApS pdf download